Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study
- 25 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Endocrinological Investigation
- Vol. 43 (12), 1759-1768
- https://doi.org/10.1007/s40618-020-01341-2
Abstract
Background The insulin-like growth factor-1 receptor (IGF-1R) is a key element in the pathogenesis of Graves’ Orbitopathy (GO), but the role of IGF-1R autoantibodies (IGF-1RAbs) has not been established. Methods We designed a cross-sectional investigation to measure IGF-1RAbs in patients with Graves’ disease (GD), with or without GO, who underwent radioiodine therapy followed by glucocorticoids (GC). Twenty-nine patients were included, 15 of which with GO. Patients were evaluated at baseline and three and 6 months after radioiodine. The primary objective was the prevalence of positive tests for IGF-1RAbs. The secondary objectives were: (1) IGF-1RAbs concentrations and their variations; (2) relationship between IGF-1RAbs and the features of GO; (3) relationship between IGF-1RAbs and anti-thyroid autoantibodies. Results IGF-1RAbs above the cut-off value were found only in one patient with GD without GO. IGF-1RAb levels were greater in patients with GD without GO, at baseline (P < 0.0001), and after three (P < 0.0001) and six (P = 0.0001) months. No correlations were observed between IGF-1RAbs and the features of GO, nor between IGF-1RAbs and anti-thyroglobulin or anti-thyroperoxidase autoantibodies. There was an inverse correlation between anti-TSH receptor autoantibodies (TRAbs) and IGF-1RAb levels in GD patients with GO at 6 months (P = 0.03). Conclusions IGF-1RAbs appear to be greater in patients with GD without GO compared with those with GO, suggesting a putative protective role of IGF-1RAbs on the development of GO, in line with the beneficial effects of Teprotumumab on GO. The inverse correlation between IGF-1RAbs and TRAbs 6 months after radioiodine may reflect antigen spreading and/or GC treatment.Keywords
Funding Information
- Università di Pisa
This publication has 33 references indexed in Scilit:
- Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' OphthalmopathyJournal of Clinical Endocrinology & Metabolism, 2013
- Autoantibodies to the IGF1 Receptor in Graves' OrbitopathyJournal of Clinical Endocrinology & Metabolism, 2013
- Thyroid Volume and Severity of Graves' OrbitopathyThyroid®, 2013
- Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathyBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- Autoimmunity in Graves' Ophthalmopathy: The Result of an Unfortunate Marriage Between TSH Receptors and IGF-1 Receptors?Journal of Clinical Endocrinology & Metabolism, 2011
- Exophthalmometric values and their biometric correlates: The Kandy Eye StudyClinical & Experimental Ophthalmology, 2009
- Normal Values of Hertel Exophthalmometry in Children, Teenagers, and Adults from Tehran, IranOptometry and Vision Science, 2008
- Unique Attributes of Orbital Fibroblasts and Global Alterations in IGF-1 Receptor Signaling Could Explain Thyroid-Associated OphthalmopathyThyroid®, 2008
- Exophthalmometric Values in a Normal Turkish Population Living in the Northeastern Part of TurkeyThyroid®, 2007
- Autoantibodies to Igf-1 Binding Sites in Thyroid Associated OphthalmopathyAutoimmunity, 1993